Podcasts about infectious diseases

Brucella is a familiar name in the lab—but recent updates to the sentinel guidelines are reshaping how we approach this pathogen. In this episode, I'm joined by Dr. Laura Filkins and Dr. Paige Larkin to discuss the latest changes: updates in nomenclature, the removal of certain Brucella species from the select agent list, and the renewed emphasis on safety in the lab. We dive into taxonomy controversies, clinical features of brucellosis, and practical steps laboratorians can take to protect themselves while delivering accurate results. Whether you're a student, laboratorian, or clinician, this conversation highlights what you need to know about the evolving landscape of Brucella diagnostics and safety.   Resources from this episode: CDC's Brucellosis Information Page ASM Updates on Brucella Stay connected with Let's Talk Micro: Website: letstalkmicro.com Questions or feedback? Email me at letstalkmicro@outlook.com Support the podcast: Venmo Buy me a Ko-fi  

Darshali Vyas is a pulmonary and critical care fellow at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.A. Vyas, L.G. Eisenstein, and D.S. Jones. The Race-Correction Debates — Progress, Tensions, and Future Directions. N Engl J Med 2025;393:1029-1036.

  Ever since the world was overtaken by the COVID-19 pandemic, public health policy and vaccine policy have been front and center in the national political debate. And tragically, despite a longstanding and overwhelming consensus among public health experts across the globe about the efficacy of vaccines and their vital importance in protecting human health […]

On this week's How on Earth, Beth describes recent developments in defunding NIH research and CDC limits on vaccine availability; then digs into vaccine safety and development with global vaccine expert, Dr Dr Kawsar Talaat. Dr Talaat is a physician who is board certified in Pediatrics, Internal Medicine and Infectious Diseases and whose research focuses … Continue reading "The (ever-changing) Scoop on Vaccines"

Dr. Arti Barnes, Chief Medical Officer at the Illinois Department of Public Health, describes how her agency is working collaboratively with other state departments to enhance access to pediatric vaccinations; Jeffrey Ekoma, Senior Director of Government Affairs at ASTHO, discusses changes to the CDC, this month's federal funding deadline, and more news from Capitol Hill in this week's View From Washington, D.C. report; a full-length recording of ASTHO's webinar on Navigating Ethical Issues in Wastewater Surveillance for Infectious Diseases is now available online; and ASTHO congratulates new member Dr. John Dunn on his appointment as Interim Commissioner for the Tennessee Department of Health.  ASTHO Newscast: 925: KFF Tracking Poll, Youth Vaccines ASTHO Legislative Alert: Summary of FY26 House LHHS Appropriations Bill ASTHO Web Page: INSPIRE: Readiness - Navigating Ethical Issues in Wastewater Surveillance for Infectious Diseases John Dunn Bio  

Dr Irene Grant is an Infectious Disease specialist with expertise in infectious complications in the immunocompromised and unusual infections in the immunocompetent. In the 1980's, in the midst of the HIV/AIDS epidemic, she trained at Memorial Sloan-Kettering Cancer Center in New York City, under Dr. Donald Armstrong (former President of the Infectious Disease Society of America) where she acquired training in Microbiology and Hospital Infection Control. Thereafter she spent years in academic medicine as an Assistant Professor of Medicine at Albert Einstein College of Medicine (1988 – 2000) and later Clinical Assistant Professor of Medicine at New York Medical College, involved in teaching, clinical epidemiology, and research, while treating inner city patients in the HIV “epicenter” in the Bronx. Later, in private practice, she applied her experience investigating unusual illnesses to help her patients sick from hazardous indoor exposures. For the past 24 years, she has evaluated and treated hundreds of debilitated patients and families with environmentally proven hazardous microbial exposures, correlating the development of multi-system illness with hazardous exposures, the reliability of diagnostic tests, and efficacy of anti-fungal treatment.

Antimicrobial resistance (AMR) continues to grow as a global health threat, making infections harder to treat and leaving fewer options for patients. The need for new antibiotics is an urgent matter — but traditional discovery methods are slow and limited. In this episode of Let's Talk Micro, Luis is joined by Dr. James Collins, professor at MIT and researcher at the Broad Institute, who is leading efforts to apply AI to antibiotic discovery. We discuss how his team used deep learning to uncover promising new compounds, including NG1 and DN1, which showed activity against drug-resistant Neisseria gonorrhoeae and Staphylococcus aureus. We also talk about the challenges of bringing discoveries from computer models to the clinic, and what this approach could mean for the future of the fight against superbugs.   Link to study: https://www.cell.com/cell/abstract/S0092-8674%2825%2900855-4   Check out the website: https://www.letstalkmicro.com/ Questions? Feedback? Send those to letstalkmicro@outlook.com Want to support the podcast? Here's how: Venmo: https://venmo.com/u/letstalkmicro Buy me a Ko-fi: https://ko-fi.com/letstalkmicro  

Send us a textIn this inspiring episode, Anne E. Goldfeld, MD—physician-scientist, humanitarian, and recipient of the 2025 Jimmy and Rosalynn Carter Humanitarian Award—joins Marla Dalton, CAE, and William Schaffner, MD, to reflect on a remarkable career in medicine, science, and global health. From treating patients in refugee camps along the Thai-Cambodian border to conducting groundbreaking research at Harvard Medical School and Boston Children's Hospital, Goldfeld shares the path that led her to a career that is tackling 2 of the greatest epidemics of our time: tuberculosis and HIV/AIDS.Show NotesA native Californian, Dr. Goldfeld attended Brown University and the University of California, Berkeley, and earned her medical degree from Albert Einstein College of Medicine. She completed her internship and residency in internal medicine and a clinical fellowship in infectious diseases at the Massachusetts General Hospital followed by a postdoctoral research training in molecular biology at Harvard University. She is Professor of Medicine and Pediatrics at Harvard Medical School and a Senior Investigator in the Program in Cellular and Molecular Medicine at Boston Children's Hospital, where her research laboratory is located. She is also Professor of Immunology and Infectious Disease at the Harvard TH Chan School of Public Health and a physician in the infectious disease division of Brigham and Women's Hospital. On the frontlines of the TB and AIDS crises, Dr. Goldfeld co founded transformative treatment and research programs—bringing care to some of the world's most underserved populations—that have led to fundamental discoveries that have saved countless lives.Follow NFID on social media

Guest: Francis Farraye, MD Host: Peter Buch, MD, FACG, AGAF, FACP A 2025 update to the American College of Gastroenterology (ACG)'s guideline on preventive care in inflammatory bowel disease (IBD) includes key changes impacting vaccine recommendations, dermatologic screening, and care coordination. Dr. Peter Buch sits down with Dr. Francis Farraye, lead author of this guideline, to highlight what clinicians need to know. Dr. Farraye is a Professor of Medicine and the Director of the Inflammatory Bowel Disease Center at the Mayo Clinic in Jacksonville, Florida

On episode #88 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 8/19/25 – 8/27/25. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination (CDC: MMWR) Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial (LANCET: HIV) Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial (CID) Bacterial Exposure to suppressive antibiotic therapy in women with recurrent urinary tract infections and severity of infections: a retrospective population-based cohort study (BMJ Open) Effectiveness and safety of antibiotics in kidney transplant recipients with asymptomatic bacteriuria: a systematic review and meta-analysis of randomized controlled trials (OFID) Epidemiological, temporal, and geographic trends of leptospirosis in the United States, 2014–2020 (PLoS Neglected Tropical Diseases) Performance of Tongue Swabs for Tuberculosis Diagnosis in Hospitalized Children Under 5 Years of Age (OFID) Fungal The Last of US Season 2 (YouTube) Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults (LANCET: Infectious Diseases) Parasitic Outcomes of Military Blood Donors at Joint Base San Antonio with Reactive Trypanosoma cruzi Antibody Screening (OFID) Cutaneous acanthamoebiasis: Two Cases Highlighting Diverse Histopathologic Findings (Journal of Cutaneous Pathology) Miscellaneous Linezolid-related Optic Nerve Disorders: Insight from a Pharmacovigilance Analysis of the U.S. FDA Adverse Event Reporting System (OFID) Extreme variability in linezolid concentrations in the ICU: A case for routine therapeutic drug monitoring (American Journal of Health-System Pharmacy) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

The germ theory of disease is one of the greatest breakthroughs in human history. But it took more than 2,000 years of false starts and resistance before medicine finally recognized that germs cause disease. In his book Germ Theory, Dr. Robert Gaynes unpacks why this shift was so hard to achieve. In this episode, he and Dart explore what it teaches us about paradigm shifts today: why new ideas face such resistance, how the personalities of innovators influence acceptance, and what happens when a powerful new paradigm leads us to overcorrect.Dr. Robert P. Gaynes is an infectious disease physician and Professor of Medicine at Emory University. He is the author of Germ Theory, a CHOICE Outstanding Academic Title.In this episode, Dart and Robert discuss:- Why it took centuries to accept that germs cause disease- What resistance to handwashing reveals about change- Breakthroughs Robert witnessed in his career- How medicine's history reveals patterns of change- HIV's transformation from fatal to treatable- What happens when new paradigms go too far- How personality shapes whether innovations are accepted- Lessons for anyone driving change at work today- And other topics…Dr. Robert P. Gaynes is an infectious disease physician and Professor of Medicine at Emory University. He chairs Emory's Infection Control and Antimicrobial Stewardship Committees, attends at the Atlanta VA Medical Center, and has written extensively on hospital-acquired infections and antimicrobial use. He is the author of Germ Theory: Medical Pioneers in Infectious Disease, named a CHOICE Outstanding Academic Title.Resources Mentioned:Germ Theory: Medical Pioneers in Infectious Disease by Robert Gaynes: https://www.amazon.com/Germ-Theory-Pioneers-Infectious-Diseases/dp/168367376XGet discounted tickets to the Responsive Conference, featuring past Work for Humans guests Bree Groff and Simone Stolzoff – September 17–18, Oakland, CA. Use code “11fold”: https://www.responsiveconference.com/ticketsRegister to attend the UWEBC Conference, where Dart keynotes the HR track alongside Ethan Mollick and Nancy Giordano – September 30, University of Wisconsin: https://uwebc.wisc.edu/conference/registration/Connect with Robert:LinkedIn: https://www.linkedin.com/in/robert-p-gaynes-49b1541/Work with Dart:Dart is the CEO and co-founder of the work design firm 11fold. Build work that makes employees feel alive, connected to their work, and focused on what's most important to the business. Book a call at 11fold.com.

In episode 85 of the Medical Nursing Podcast, we're finishing our infectious disease series with a group of diseases that are increasingly common but often overlooked, and that's tick-borne disease. I had NO idea what these were when I worked in general practice. The first time I ever heard of it was when a dog from a nearby rescue centre we worked with had a bleeding disorder, and the vet mentioned Ehrlichia. I had no idea what it was, but the patient needed a lot of care. Tick-borne disease is on the rise, and there's a good chance you'll see it - particularly if you work in first opinion practice, internal medicine, emergency and critical care, or rescue and rehoming settings. When I say tick-borne disease, I'll cover four main conditions. These are: Borrelia burgdorferi, which causes Lyme disease Anaplasma phagocytophilum Ehrlichia canis And Babesia species, most commonly Babesia canis In the episode, we'll look at what each of these diseases causes, how they present, how we test for and treat them, and - most importantly for us - what we can do as nurses and technicians to care for these patients. --- BRAND NEW ways to learn with me:

Legionella remains one of the most complex challenges for water professionals worldwide. How do we balance effective monitoring with realistic costs—and which strategies deliver true public health impact? In this episode, Trace Blackmore welcomes Dr. Vincenzo Romano Spica,  Head Public Health University of Rome "Foro Italico to explore new insights from his comparative research on Legionella control. Reframing Legionella Risk  Dr. Spica explains why public health data increasingly points to Legionella pneumophila—not all Legionella species—as the primary concern for human health. He shares how pan-European data modeling and peer-reviewed studies demonstrate that broad-spectrum monitoring may overburden systems without delivering proportional safety gains.  Cost-Benefit Models and Sustainability  Water professionals know that testing and compliance require resources. Dr. Spica discusses cost-benefit analysis frameworks that help decision-makers evaluate where investments deliver the greatest reduction in risk. He also highlights the sustainability implications of over-testing, from lab resources to environmental waste streams.  European Regulations and Legal Liability  The conversation also explores the European Drinking Water Directive 2020/2184, national approaches to Legionella, and how liability shifts when contamination is detected. Dr. Spica's insights illuminate what building owners, operators, and regulators must weigh as they update management plans.  Conclusion  For engineers, operators, and technical managers, this episode provides a clear framework for thinking about Legionella beyond routine testing. It's about focusing on the pathogen that truly drives disease outcomes, aligning regulatory strategy with science, and applying resources where they matter most.  Stay engaged, keep learning, and continue scaling up your knowledge!    Timestamps    02:24 - Trace opens the episode, welcoming listeners to Legionella Awareness Month and framing the call to action  05:37 - Water You Know with James McDonald  10:04 - Upcoming Events for Water Treatment Professionals   14:06 - Trace introduces Dr. Vincenzo Romano Spica, Head of Public Health at the University of Rome Foro Italico   17:22 - Dr. Spica outlines why Legionella pneumophila is the main pathogen of concern in Europe 35:04 - Dr. Spica explains Disability Adjusted Life Years (DALYs) as a measure of public health burden  44:08 - Monitoring strategies and how different culture methods affect outcomes  46:16 - The role of water temperature in Legionella proliferation    Quotes  “Not all Legionella are equal—public health data shows us it's Legionella pneumophila that drives the real risk.”  “Testing everything may look safer on paper, but in practice, it diverts resources from where they can have the greatest impact.”  “Risk management should not be a checklist; it should be a strategic allocation of resources aligned with outcomes.”  “European data models show that a targeted approach can deliver both better safety and greater sustainability.”    Connect with Dr. Vincenzo Romano Spica   Phone: +39.06.36733247 Email: vincenzo.romanospica@uniroma4.it  LinkedIn: vincenzo romano spica | LinkedIn        Guest Resources Mentioned   Legionnaires' Disease Surveillance and Public Health Policies in Italy: A Mathematical Model for Assessing Prevention Strategies by Dr. Spica et. al  Alessando Cassini's Burden of Infectious Diseases in Europe methodological challenges and opportunities for public health policy  NLM's Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013  Supplemental information: Impact of UAT Diagnostic Methods on Estimates of Legionnaires' disease Caused by non-pneumophila Legionella    Scaling UP! H2O Resources Mentioned  AWT (Association of Water Technologies)  Scaling UP! H2O Academy video courses  Submit a Show Idea  Scaling UP! H2O's Legionella Resources Library  434 Encore Interview with Patsy Root    Water You Know with James McDonald  Question: What is it called when a valve is closed at the end of a pipeline system causing a pressure wave to propagate in the pipe and a loud banging sound?    2025 Events for Water Professionals  Check out our Scaling UP! H2O Events Calendar where we've listed every event Water Treaters should be aware of by clicking HERE.     

What if the "wrong" career moves are actually the right ones? And what happens when a physician decides the traditional path isn't enough? For Dr. Meklit Workneh, the answer to these questions was a journey that took her from Ethiopia to Stanford, through public health fieldwork, FDA regulatory medicine, and ultimately to leading AI-integrated clinical trials at Moderna. Her story proves that curiosity, courage, and strategic career pivots can transform not just your own trajectory—but also advance global health innovation. From arriving solo in California at 17 to becoming a triple board-certified physician pioneering the intersection of artificial intelligence and clinical development, Dr. Workneh's path offers practical insights for anyone ready to create their own career rather than follow someone else's blueprint. The Intersectional Advantage Dr. Workneh brings a unique perspective shaped by multiple intersections: An Ethiopian immigrant who arrived in the US solo at 17 for college Triple board-certified physician with expertise spanning clinical care, research, and pathology Mother of young children balancing executive leadership with family life First-generation professional navigating American corporate structures Bridge-builder between medicine, technology, public health, and industry Black woman in biotech leadership championing diversity in clinical trials As she puts it: "I've always been that person where I'm going to find all the things I like doing and bring them all together and find a way to do it." The Journey: From Ethiopia to Stanford to Biopharma Early Life in East Africa: Born in Ethiopia during the communist era, experienced family relocation to Kenya during political upheaval, and returned to Ethiopia for high school education. Bold Educational Move: At 17, made the independent decision to attend Stanford University, arriving solo in California—a culture shock that required significant adaptation and resilience. Strategic Academic Path: Studied biology at Stanford, then pursued an MPH at Yale focused on public health, worked in field research in Ethiopia before medical school. Medical Training Excellence: Earned MD from UCSF, completed internal medicine residency and infectious diseases/microbiology fellowship at Johns Hopkins. Government Service: Joined the FDA's Division of Infectious Diseases, working on neglected tropical diseases, antibiotic resistance, and the COVID-19 pandemic response. Industry Leadership: Transitioned to Moderna as Senior Director of Clinical Development, pioneering AI integration in infectious disease clinical trials. Essential Career Insights Maintain Curiosity Above All: "I think it always helps to maintain a degree of curiosity, no matter what you do, and just keep learning. Keep exploring. You never know the opportunities that your curiosity will open up." Think Holistically About Life Design: Consider how your career choices align with your personal goals, including family, lifestyle, and values. "I wanted to have children, to get married, all of those things were important to me….so thinking about how do I merge all of these things." Create Your Own Specialization: Don't be limited by traditional career tracks. "I was always exploring all these interests…like Africa, public health, infectious disease... And I'm just gonna take a bunch of things and just merge them together." Seek Information Through Relationships: "I just really try to keep an open mind. You know, went to things that were sort of outside my comfort zone and I talked to a lot of people... let me see what they're doing and sort of keep a very open mind." Embrace the Non-Linear Path: "I didn't even know this was a career path when I started out... it wasn't necessarily a well-crafted plan to end up exactly where I am now. But, you know, I'm very happy with where I am now." About Our Guest Dr. Meklit Workneh is a Senior Director of Clinical Development in Infectious Diseases at Moderna Therapeutics, where she leads teams designing clinical trials and developing strategies that bring life-saving vaccines and therapeutics to patients worldwide. She is triple board-certified in internal medicine, infectious diseases, and pathology (microbiology) with over 15 years of experience bridging clinical medicine and research. Her groundbreaking work at the intersection of AI and clinical development recently gained national recognition through Moderna's partnership with OpenAI, showcasing how intelligent technology can accelerate the path from discovery to treatment. Before joining industry, she served at the FDA's Division of Infectious Diseases, working on neglected tropical diseases, antibiotic resistance, and COVID-19 initiatives. Dr. Workneh holds a BA from Stanford University, an MPH from Yale School of Public Health, and an MD from University of California, San Francisco. She completed her residency in internal medicine and fellowship training in infectious diseases and microbiology at Johns Hopkins. Connect with Guest Dr. Meklit Workneh LinkedIn: Dr. Meklit WorknehExpertise: Clinical Trial Design, AI in Healthcare, Biotech Leadership, Infectious Disease Medicine Collaboration Interest: Advancing diversity in clinical trials and global health innovation About the Host Dr. Lola Adeyemo is the CEO of EQI Mindset and founder of the nonprofit Immigrants Incorporate Inc. She works with organizations to build inclusive workplaces and amplifies the voices of leaders and immigrants in the corporate space. Want to Get Involved? If you are a leader with a story to share - apply to be on the podcast: Application Link Join Immigrants in Corporate Non-Profit Community for FREE! Are you an HR, Culture, or DEI Leader? Email Lola@EQImindset.com to Get Your Workplace Community Employee Resource Groups (ERGs / BRGs) Launched, Leveraged, and Thriving! This episode of Thriving in Intersectionality is perfect for anyone who's ever felt like they don't fit into traditional career boxes - because sometimes the most extraordinary paths are the ones you create yourself.

In this episode host Marc Goldberg interviews Rogue Community College (RCC) and Southern Oregon University (SOU) graduate Jahna Thompson, Rogue Community College president, Dr. Randy Weber and Director, Postsecondary Success at The Ford Family Foundation, Denise Callahan. Jahna emphasizes the value of strong faculty mentorship and advising from her student experience at both Rogue Community College and SOU with a unique lens of having taught in her field of study at both institutions as a faculty/professor over the past year. She elaborates on her academic journey that began taking GED prep classes at RCC and after completing her Bachelor's and Master's degrees, she is currently pursuing a PhD in Immunology & Infectious Disease at Washington State University.President Weber reflects on Jahna's interview and describes specific college efforts through responsive programming, student supports and community partnerships that have helped increase enrollment and improve retention and completion outcomes for students, including those who enter the college taking adult education courses. Denise highlights the Foundation's impactful postsecondary education work across Oregon,  particularly in rural communities, through Foundation investments, scholarships and research. She describes how the Foundation's work supporting over 1000 postsecondary education students annually across Oregon through scholarships helps inform the organization's policy and research work and shares more on the recently released Oregon by the Numbers report by the Foundation that offers a detailed profile for each of Oregon's 36 counties. The All In: Student Pathways Forward podcast is a part of Oregon's participation in the National Skills Coalition SkillSPAN network.

In episode 55 of Going anti-Viral, Dr Darcy Wooten joins host Dr Michael Saag to discuss navigating HIV care with glucagon-like peptide-1 (GLP-1) receptor agonists. Dr Wooten is a Professor of Medicine in the Division of Infectious Diseases at Washington University in St. Louis. Her clinical interests are HIV primary care, HIV prevention, sexually transmitted infections, and general infectious diseases. Dr Wooten is also a national leader in medical education. Dr Wooten provides an overview of GLP-1 receptor agonists including their history of use for the treatment of diabetes and more recent use for treatment of weight loss. Dr Saag and Dr Wooten discuss the challenges that patients have in getting insurance coverage for GLP-1 receptor agonists and review the 2 most common drugs that are used as treatment, tirzepatide and semaglutide. They discuss the patient experience with the injectable medication and review the possibility of oral versions of the medications in the future. Finally, Dr Saag and Dr Wooten discuss the long-term management of GLP-1 receptor agonists as a part of overall primary care for patients with HIV.0:00 – Introduction1:11 – Overview of GLP-1 receptor agonists3:46 – How GLP-1 receptor agonists became used for weight management and patient eligibility criteria6:14 – Challenges of insurance coverage for GLP-1 receptor agonists8:32 – Differences between theGLP-1 receptor agonists tirzepatide and semaglutide and other benefits of the medications beyond weight loss12:04 – Patient experience with the injectable formulations and possible adverse effects of use14:36 – Long-term use of GLP-1 receptor agonists and possibility of oral versions of these drugs17:36 – Managing GLP-1 receptor agonists as a part of primary care for patients with HIV including treatment of some substance use disorders20:22 – Predictions for future management of GLP-1 receptor agonists and Dr Wooten's hope for more research into incorporating lifestyle modifications into patient care __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In October (5th) Siobhan, who hails from Clare, and her son will undertake a big challenge in memory of her late brother. They will take on Ironman Barcelona in aid of the Irish Motor Neurone Disease Association to commemorate Siobhan's brother, Michael Carmody. To discuss this further, Alan Morrissey was joined by Siobhan O'Dea, Professional Advanced Nurse Practitioner in Infectious Diseases at St. Vincent's Hospital. You can support Siobhan here: https://www.idonate.ie/fundraiser/SiobhanAndLuke

Fungal infections and disease have long been overlooked in terms of healthcare burden, with poor diagnostics and limited options for treatment and management. In 2022, the WHO published its first Fungal Priority Pathogens List as an effort to establish a global prioritised framework that addresses unmet research and development needs in fungal disease and antifungal resistance, as well as guides public health action [1]. In this episode of Communicable, Angela Huttner and Josh Nosanchuk invite Hatim Sati (WHO), the project lead in creating this list, and Dimitrios Kontoyiannis (MD Anderson Cancer Center, Houston, Texas), a clinician researcher studying fungal diagnostics and antifungal discovery, for a candid discussion on the making of and relevance of such a list. Apart from reviewing the fungal pathogens, the conversation also covers limitations of the list, what to expect for the next iteration, contextualising the list in one's local region, and the impact the list has had already on research funding and public awareness.This episode was edited by Kathryn Hostettler and peer reviewed by Andrisa Xhaxha from Elbasan, Albania. ReferencesWHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022. Related podcast episodesCommunicable Episode 31: Climate change and fungal spread https://share.transistor.fm/s/db58f558 Communicable Episode 08: The nightmare series, part 1 – how to deal with Candida auris https://share.transistor.fm/s/c0616c4d Further reading Seidel D, et al. Impact of climate change and natural disasters on fungal infections. Lancet Microbe 2024. DOI: 10.1016/S2666-5247(24)00039-9Fisher MC and Denning DW. The WHO fungal priority pathogens list as a gamechanger. Nat Rev Microbiol 2023. DOI: 10.1038/s41579-023-00861-xShor E, et al. Tolerance and heteroresistance to echinocandins in Candida auris: conceptual issues, clinical implications, and outstanding questions. mSphere 2025. DOI: 10.1128/msphere.00161-25Panackal AA, et al. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis 2010. DOI: 10.1086/652761Lázár-Molnár E, et al. The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum. PNAS 2008. DOI: 10.1073/pnas.0711918105Mashal M, “A potentially fatal fungal infections cropping up among India's Covid patients.” New York Times 2021. https://www.nytimes.com/2021/05/09/world/india-covid-mucormycosis.html Thevissen K, et al. International survey on influenza-associated pulmonary aspergillosis (IAPA) in intensive care units: responses suggest low awareness and potential underdiagnosis outside Europe. Crit Care 2020. DOI: 10.1186/s13054-020-2808-8Pappas PG, et al. Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27–30, 2018, Big Sky, Montana, a proposed global research agenda. Medical Mycology 2020. DOI: 10.1093/mmy/myaa034Hostettler K, et al. Communicable Episode 31: Climate change and fungal spread. CMI Communications 2025. DOI: 10.1016/j.cmicom.2025.105126

Dr. John Greene, Professor of Medicine and Chief of Infectious Diseases at Moffitt Cancer and Research Institute, conducts this photo review of various human endemic fungal infections. Covered topics include mycetoma, chromoblastomycosis, phaeohyphomycosis, Sporotrichosis, cryptococcosis, histoplasmosis, blastomycosis, coccidioidomycosis, and paracoccidioidomycosis. The presentation is suitable for infectious diseases board examination testing.

This member-driven podcast is a benefit of membership of the Arizona Chapter of the American Academy of Pediatrics (AzAAP) and is intended for AzAAP pediatric healthcare members.AzAAP would like to acknowledge the generous support of the podcast by the Arizona Department of Health Services through the Title V Maternal and Child Health Services Block Grant funding. No information or content in this podcast is intended to substitute or replace a consultation with a healthcare provider or specialist. All non-healthcare providers should reach out to their child's pediatrician for guidance. Music: Wallpaper by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/4604-wallpaperLicense: http://creativecommons.org/licenses/by/4.0/ 

In this episode of Let's Talk Micro, Dr. Jennifer Dien Bard and Dr. Lucas Osborn discuss their recent study on early growth antimicrobial susceptibility testing (AST). Traditional AST often requires 18–24 hours of incubation of isolates, delaying targeted treatment. Their research shows that using 6-hour early growth isolates with both automated and manual methods delivers accurate results up to 18 hours faster—without added costs or specialized equipment. The conversation explores the study design, agreement rates with standard methods, and what faster AST means for patient care and antimicrobial stewardship.  Link to study: https://doi.org/10.1128/jcm.00236-25 Link to disk diffusion study: https://doi.org/10.1128/jcm.03007-20   Check out the website: https://www.letstalkmicro.com/ Questions? Feedback? Send those to letstalkmicro@outlook.com Want to support the podcast? Here's how: Venmo: https://venmo.com/u/letstalkmicro Buy me a Ko-fi: https://ko-fi.com/letstalkmicro  

On episode #87 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 7/31/25 – 8/18/25. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Adjuvanted recombinant zoster vaccine is effective against herpes zoster ophthalmicus, and is associated with lower risk of acute myocardial infarction and stroke in adults aged ≥50 years (CID) Bacterial Dalbavancin for Treatment of Staphylococcus aureus Bacteremia (JAMA) Propensity-Matched Comparison of Timely vs. Delayed Antibiotic Therapy in Stenotrophomonas maltophilia Pneumoni (OFID) The proportion of Treponema pallidum PCR-positive primary syphilis infections which are seronegative for syphilis (OFID) Cefixime versus benzathine penicillin G for the treatment of early syphilis (Journal of Antimicrobial Chemotherapy) Dalbavancin for Treatment of Staphylococcus aureus Bacteremia (JAMA) Fungal The Last of US Season 2 (YouTube) Parasitic Increasing Length of the Babesia Season in New England in the Climate Change Era (OFID) Ivermectin to Control Malaria (NEJM) Miscellaneous ACIP Recommendations Summary (CDC: Influenza) Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to frailty score (JID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Dr Robert T. Ball, Jr.  joins Ethics Talk to discuss his article: “Why Should Clinicians Care About Infectious Disease Existential Hazards?”  Recorded May 20, 2025.  Read the full article for free at JournalOfEthics.org

Dr. Ambika Eranki, Assistant Professor at the Division of Infectious Diseases and International Medicine, presents this review of infections associated with native and prosthetic joints, in addition to infectious of the spine and vertebrae. Dr. Eranki begins by presenting some case based examples of bone and joint infections. She then discusses the definitions and workup of infectious arthritis, septic arthritis, vertebral osteomyelitis, and prosthetic joint infections. A brief review of infections of the diabetic foot is also presented. Dr. Eranki closes by sharing recent important medical publications for bone and joint infections and the diabetic foot.

This week, Luis is joined by Dr. Ashlan Kunz-Coyne to discuss some of the newest antibiotics for urinary tract infections (UTIs). They explore why extended-spectrum beta-lactamases (ESBLs) are a growing concern, the impact of E. coli sequence type 131, and where new agents like cefepime–enmetazobactam, sulopenem, and tebipenem fit into treatment. The conversation also highlights clinical data, stewardship considerations, and how the infectious diseases and microbiology communities can work together to preserve these options. Plus, Dr. Kunz-Coyne reveals her favorite bug—Stenotrophomonas maltophilia—and why it's unlike any other.    Link to sulopenem episode: https://directory.libsyn.com/episode/index/id/35868135   Check out the website: https://www.letstalkmicro.com/ Questions? Feedback? Send those to letstalkmicro@outlook.com Want to support the podcast? Here's how: Venmo: https://venmo.com/u/letstalkmicro Buy me a Ko-fi: https://ko-fi.com/letstalkmicro  

Tom Frieden is the president and chief executive officer of Resolve to Save Lives and former director of the Centers for Disease Control and Prevention. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. T.R. Frieden. Dismantling Public Health Infrastructure, Endangering American Lives. N Engl J Med 2025;393:625-627.

Hear from experts in HIV care Beatriz Grinsztejn, MD, PhD, and Rosie Mnggibisa, MBChB, MPH, as they discuss their insights on some of the most clinically relevant new data presented at IAS 2025, including studies on: Gaps in care for adolescents and young adults living with HIVGlobal impact of funding cutsAntiretroviral therapy for treating HIVPatient management strategies for people living with HIV and obesityPresenters:Beatriz Grinsztejn, MD, PhDDirectorSTI/HIV Clinical Research LaboratoryEvandro Chagas National Institute of Infectious Diseases – FIOCRUZRio de Janeiro, BrazilRosie Mngqibisa, MBChB, MPHClinical DirectorPrincipal InvestigatorEnhancing Care FoundationDurban, South AfricaLink to full program: https://bit.ly/4otF8AR

In episode 54 of Going anti-Viral, Dr Ellen Eaton joins host Dr Michael Saag to discuss the treatment of substance use disorder in an in-patient setting. Dr Eaton is an Associate Professor in the Department of Medicine and Division of Infectious Diseases at the University of Alabama at Birmingham (UAB). Dr Eaton provides and update on a recent termination of a Center for Disease Control and Prevention (CDC) grant that provided overdose prevention education and treatment. She discusses the impact that a recent executive order on unhoused individuals that may have on access to care. Dr Eaton addresses a recent “bad batch” alert warning of contaminated street drugs leading to serious overdose events, and the most common reasons that people are admitted for in-patient care and review treatment of substance use disorder-related infections. They review acute withdrawal in the hospital and Dr Eaton shares her ideal response to substance use disorder in a hospital setting. Finally, Dr Saag and Dr Eaton look forward to the next 10 years of care for people with substance use disorder.0:00 – Introduction1:19 – Update on current issues including access to naloxone and a recent executive order on unhoused individuals4:43 – Update on recent “bad batch” alert regarding serious overdose events7:27 – The most common reasons why people are admitted for in-patient care 11:03 – Treatment of substance use disorder-related infections particularly where prolonged antimicrobial therapy is needed and discussion of the use of a PICC line16:07 – Treatment and preventing acute withdrawal in the hospital including administration of buprenorphine21:46 – The ideal response to substance use disorder in a hospital setting27:00 – How treatment of substance use disorder may improve in the next 10 years__________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

This member-driven podcast is a benefit of membership of the Arizona Chapter of the American Academy of Pediatrics (AzAAP) and is intended for AzAAP pediatric healthcare members.AzAAP would like to acknowledge the generous support of the podcast by the Arizona Department of Health Services through the Title V Maternal and Child Health Services Block Grant funding. No information or content in this podcast is intended to substitute or replace a consultation with a healthcare provider or specialist. All non-healthcare providers should reach out to their child's pediatrician for guidance. Music: Wallpaper by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/4604-wallpaperLicense: http://creativecommons.org/licenses/by/4.0/ 

Welcome to the Choosing Wisely Campaign series! This is the fourth episode of a 5-part series exploring the ABIM Foundation's Choosing Wisely Lists. This campaign aims to promote conversations between clinicians and patients to avoid unnecessary medical tests, treatments, and procedures. Our third case-based episode presents a child with fever and cough. After a clear discussion of the case and thoughtful consideration of the etiology and treatment strategies, we use the AAP's Choosing Wisely Hospital Medicine and Infectious Diseases lists to create a resource-conscious care plan that is safe and patient-centered. In the coming episodes, we'll explore the pediatric lists and apply our knowledge to cases of common presentations seen in primary and acute care pediatrics.    Series Learning Objectives: Introduction to the Choosing Wisely Campaign: Understand the origins, historical precedent, and primary goals of the campaign. Case-Based Applications: Explore five common presentations in primary and acute care pediatrics, applying concepts from various Choosing Wisely lists to guide management and resource stewardship. Effective Communication: Learn strategies for engaging in tough conversations with parents and colleagues to create allies and ensure evidence-based practices are followed. Modified rMETRIQ Score: 14/15   Competencies: AACN Essentials: 1: 1.1 g; 1.2 f; 1.3 d, e 2: 2.1 d, e; 2.2 g; 2.4 f, g; 2.5 h, i, j, k 7: 7.2 g, h, k 9: 9.1i, j; 9.2 i, j; 9.3 i, k   NONPF NP Core Competencies: 1: NP 1.1h; NP 1.2 k, m; NP 1.3 f, j, h 2: NP 2.1 j, g; NP 2.2 k, n; NP 2.4 h, i; NP 2.5 k, l, m, n, o 7: NP 7.2 m 9: NP 9.1 m, n; NP 9.2 n; NP 9.3 p   References ABIM Foundation. (2019). Communicating about overuse with vulnerable populations. Retrieved from https://www.choosingwisely.org/files/Communicating-About-Overuse-to-Vulnerable-Population_Final2.pdf American Academy of Pediatrics [AAP] Committee on Infectious Diseases & Pediatric Infectious Diseases Society. (2018). Five things physicians and patients should question. Retrieved from https://downloads.aap.org/AAP/PDF/Choosing%20Wisely/CWInfectiousDisease.pdf de Benedictis, F. M., Kerem, E., Chang, A. B., Colin, A. A., Zar, H. J., & Bush, A. (2020). Complicated pneumonia in children. Lancet (London, England), 396(10253), 786–798. https://doi.org/10.1016/S0140-6736(20)31550-6 Kato, H. (2024) Antibiotic therapy for bacterial pneumonia. J Pharm Health Care Sci 10, 45. https://doi.org/10.1186/s40780-024-00367-5 Schlapbach, L. J., Watson, R. S., Sorce, L. R., Argent, A. C., Menon, K., Hall, M. W., Akech, S., Albers, D. J., Alpern, E. R., Balamuth, F., Bembea, M., Biban, P., Carrol, E. D., Chiotos, K., Chisti, M. J., DeWitt, P. E., Evans, I., Flauzino de Oliveira, C., Horvat, C. M., Inwald, D., … Society of Critical Care Medicine Pediatric Sepsis Definition Task Force (2024). International Consensus Criteria for Pediatric Sepsis and Septic Shock. JAMA, 331(8), 665–674. https://doi.org/10.1001/jama.2024.0179 Smith, D. K., Kuckel, D. P., & Recidoro, A. M. (2021). Community-Acquired Pneumonia in Children: Rapid Evidence Review. American family physician, 104(6), 618–625. Society of Hospital Medicine, AAP, & Academic Pediatric Association. (2021). Five things physicians and patients should question. Retrieved from https://downloads.aap.org/AAP/PDF/Choosing%20Wisely/CWHospitalmedicine.pdf Yun K. W. (2024). Community-acquired pneumonia in children: updated perspectives on its etiology, diagnosis, and treatment. Clinical and experimental pediatrics, 67(2), 80–89. https://doi.org/10.3345/cep.2022.01452

Ethics in the field of infectious disease can be a delicate interplay between treating the individual patient and protecting the collective health of a society. Sometimes these two mandates go hand in hand; at other times they can appear to be in conflict. In this episode of Communicable, Dr. Angela Huttner invites Drs. Zeb Jamrozik (Melbourne, Australia) and Beenish Syed (Karachi, Pakistan), two members of ESCMID's Ethics Advisory Committee, to unpack different scenarios encountered in the field of infectious disease from an ethics standpoint: how one ethically allocates scarce resources like antimicrobials; whether there is ethical justification for coercive public-health measures like lockdowns; and whether the need to collect evidence to advance patient care could include other models besides opt-in informed consent. This episode was edited by Dr. Kathryn Hostettler and peer reviewed by Dr. Goulia Ohan of Yerevan State Medical University, Yerevan, Armenia.Further reading:Barosa M, et al. The Ethical Obligation for Research During Public Health Emergencies: Insights From the COVID-19 Pandemic. Med Health Care Philos 2024. DOI: 10.1007/s11019-023-10184-6Symons X, et al. Why should HCWs receive priority access to vaccines in a pandemic? BMC Med Ethics 2021. DOI: 10.1186/s12910-021-00650-2Thorsteinsdottir B and Madsen BE. Prioritizing health care workers and first responders for access to the COVID19 vaccine is not unethical, but both fair and effective – an ethical analysis. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2021. DOI: 10.1186/s13049-021-00886-2Huttner A, Leibovici L, Theuretzbacher U, Huttner B, Paul M. Closing the evidence gap in infectious disease: point-of-care randomization and informed consent. Clin Microbiol Infect 2017;23(2):73-77. DOI: 10.1016/j.cmi.2016.07.029

On Thursday's show: An announced rollback of mRNA vaccine development and funding comes as Texas is among the states seeing the largest rise in COVID cases this summer. Infectious disease specialist Catherine Troisi offers her take on what the rollback means.Also this hour: A Grand Parkway expansion project is just the latest sign of ongoing growth in Greater Houston's north and west sides. We discuss the project and what is behind the growth.Then, theater productions involve a lot more than actors stepping out on stage and reciting lines. We learn how the crew behind the scenes at the Alley Theatre design and creates sets, costumes, wigs, and props for every production.And six Houston writers will be honored at the Master Wordsmith Awards on Thursday night at Kindred Stories -- not just for what they've written but also for how their words have helped heal, connect, and inspire.

Season 5 premieres today!  Antimicrobial susceptibility testing (AST) is essential for guiding effective treatment—but how has it evolved, and what challenges are we still facing? In the first episode of this series in collaboration with bioMérieux, Dr. Andrea Prinzi joins Let's Talk Micro to explore the evolution of AST—from early methods to modern platforms like VITEK 2. We discuss the known issue of outdated breakpoints in clinical practice, the challenges with regulatory hurdles, and the impact of the 21st Century Cures Act. What is the Cures Act, and how does it affect the way breakpoints are adopted? Why are delays still happening? And most importantly—what can laboratories, organizations, and manufacturers do to drive change? Tune in to understand where we've been, where we are, and where we need to go in the world of AST.   This episode is sponsored by bioMérieux, a global innovator in infectious disease diagnostics.   Resources from bioMérieux: https://info.biomerieux.com/clin_us_2024_ams_handbook?utm_source=podcast&utm_medium=show-notes&utm_campaign=LetsTalkMicro Additional breakpoint links: https://doi.org/10.1128/jcm.00106-25   Check out the website: https://www.letstalkmicro.com/ Questions? Feedback? Send those to letstalkmicro@outlook.com Want to support the podcast? Here's how: Venmo: https://venmo.com/u/letstalkmicro Buy me a Ko-fi: https://ko-fi.com/letstalkmicro

Fighting Infectious Diseases: Rachel BurgoonRachel Burgoon didn't just choose pharmacy — she chose a mission. As an infectious disease pharmacist, her work is ministry through medicine. Every treatment she recommends is driven by a deep desire to serve others and honor Christ.Her journey began in Maryland but found clarity and calling at Cedarville University, where the integration of faith and science in Cedarville's Doctor of Pharmacy program shaped her purpose.“It wasn't just about becoming a pharmacist,” Rachel explains. “It was about becoming someone who could serve the Lord by serving patients — especially the most vulnerable.”Today, Rachel works in the high-stakes world of infectious diseases, tackling complex cases involving antibiotic stewardship and life-threatening infections. Her work demands both clinical precision and heartfelt compassion.“This is critical work,” she says. “If we don't use the right therapies in the right way, we risk resistance and harm. It's a space where science must be excellent — and so must our care.”Beyond her clinical responsibilities, Rachel invests deeply in mentoring students and residents — a passion born from her own experience.  She recalls Cedarville faculty pouring into her life as a student, and she desires to mirror that service with the people she interacts with each day.Recently, Rachel shared her story on the Cedarville Stories podcast, offering listeners a glimpse into the heart behind her profession — a heart committed to glorifying God through healing and hope.Through every patient she treats, every student she mentors, and every advancement she makes in infectious disease research, Rachel Burgoon is faithfully living out her calling to reflect Christ by caring for the sick with excellence and compassion.https://share.transistor.fm/s/aee80c17https://youtu.be/a1uqw7rYSd0 

Doctors Lisa and Sara are joined by Medical Microbiology and Infectious Diseases Consultant Dr Callum Mutch for an overview of Antibiotics and Microbiology in General Practice. Doctors Callum and Jame host a podcast in Infectious Diseases called ID:IOTS and we wanted to do a crossover episode exploring common themes in Microbiology that we encounter in General Practice. We talk about the case of a woman with recurrent UTIs and a man with epididymo-orchitis. This lends itself to a discussion on general approaches to cases, microbes and antibiotics. We cover a little bit about antimicrobial stewardship at the end.    You can use these podcasts as part of your CPD - we don't do certificates but they still count :) Resources: Podcast: Infectious Diseases Insight of Two Specialists (ID:IOTS): https://www.britishinfection.org/education-events/idiots-podcast Antimicrobial Counselling Resources from Public Health Wales: https://phw.nhs.wales/services-and-teams/antibiotics-and-infections/harp-news/eaadwaaw-2021/resources/community-pharmacy-counselling-checklist/ Antimicrobial Counselling RCGP TARGET Resources: https://elearning.rcgp.org.uk/mod/book/view.php?id=12647 The Cynefin Framework for looking at decisions (Simple, complicated, Complex, Chaos): https://thecynefin.co/about-us/about-cynefin-framework/?srsltid=AfmBOopHNprchcOsISLVvXm2C5W-UU-oqHDkty_jo1IAAsupfoMu4_Cx Shared Decision Making Tool BRAN - Benefits, Risks, Alternatives, Nothing: https://www.england.nhs.uk/personalisedcare/shared-decision-making/decision-support-tools/how-to-use-a-decision-support-tool/#:~:text=Prepare%20patients%20to%20share%20decisions&text=In%20addition%20to%20the%20proactive,Nothing)%20or%20equivalent%20local%20initiatives World Health Organisation AWaRe Book: Access, Watch, Reserve Antimicrobial Book (can aid in decision making around which antibiotics to use. Accessed May 2025):  https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2022.02 UK Health Security Agency Adaptation of the Access, Watch, Reserve (AWaRe) Guidelines: https://www.gov.uk/government/publications/uk-aware-antibiotic-classification/uk-access-watch-reserve-and-other-classification-for-antibiotics-uk-aware-antibiotic-classification ___ We really want to make these episodes relevant and helpful: if you have any questions or want any particular areas covered then contact us on Twitter @PCKBpodcast, or leave a comment on our quick anonymous survey here: https://pckb.org/feedback Email us at: primarycarepodcasts@gmail.com ___ This podcast has been made with the support of GP Excellence and Greater Manchester Integrated Care Board. Given that it is recorded with Greater Manchester clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it's release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

On episode #86 of the Infectious Disease Puscast, Daniel reviews the infectious disease literature for the weeks of 7/22 – 8/1/25. Host: Daniel Griffin Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Long-term clinical sequelae among Sudan ebolavirus disease survivors 2 years post-infection (BMC Medicine) Bacterial War on AMR: High MDR carriage rates among war-injured Ukrainian refugees (CMI: Clinical Microbiology and Infection) Oral washes and tongue swabs for Xpert MTB/RIF Ultra-based tuberculosis diagnosis in people with and without the ability to make sputum (CID) Fungal The Last of US Season 2 (YouTube) Progression from Candida auris Colonization Screening to Clinical Case Status, United States, 2016–2023 (CDC: Emerging Infectious Diseases) Regional Emergence of Candida auris in Chicago and Lessons Learned From Intensive Follow-up at 1 Ventilator-Capable Skilled Nursing Facility (CID) Infection Control Guidance: Candida auris (CDC: Candida auris) Twice Weekly Sulfamethoxazole/Trimethoprim for Pneumocystis jiroveci Pneumonia Prophylaxis in Lung Transplant Recipients(Transplant Infectious Disease) Parasitic Toxoplasma gondii infection of neurons alters the production and content of extracellular vesicles directing astrocyte phenotype and contributing to the loss of GLT-1 in the infected brain (PLoS Pathogens) Baylisascariasis (Raccoon Roundworm Infection) in Two Unrelated Children  (CDC: MMWR) Miscellaneous A Review of Alpha Gal Syndrome for the Infectious Diseases Practitioner (OFID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

We're taking a breather this August as we work on bringing you more great episodes of the ATS Breathe Easy podcast. But we're not going off the air - instead, we're bringing back some of our best episodes of the last season. See you in September for season two! On this episode of ATS Breathe Easy, host Patti Tripathi welcomes two leading experts to discuss the critical role of vaccines in protecting children and high-risk populations. Paul Offit, MD, renowned scientist and vaccine advocate, and Tina Hartert, MD, MPH, professor of medicine and director of the Center for Asthma Research, provide an in-depth look at vaccine policies, hesitancy, and the consequences of declining immunization rates. 

Welcome to a world where medicine meets politics: a space that brings together scientific research, government wrangling, public push-back and healthcare conspiracies…Dr Anthony Fauci was the Director of America's National Institute of Allergy and Infectious Diseases for nearly four decades, during which time he not only helped study, treat and prevent viruses such as HIV/AIDS and Covid-19; he also advised seven US Presidents, from Ronald Regan through to Joe Biden.Along the way, Tony Fauci's picked up a public profile and taken a fair amount of flack; not least because of his complicated relationship with President Donald Trump. But he's also made great strides in medical research and policy, from working with activists who initially challenged him on the government response to HIV/AIDS - to spearheading the USA's PEPFAR project to share vital medication with developing nations.In a candid conversation with Professor Jim Al-Khalili, Tony discusses his childhood in Brooklyn, the dark early days of the HIV/AIDS epidemic and lessons from the Covid-19.Presented by Jim Al-Khalili Produced for BBC Studios by Lucy Taylor Reversion for World Service by Minnie Harrop

This episode of Let's Talk Micro features Dr. Andrea Prinzi, a clinical microbiologist and frequent contributor to the American Society for Microbiology. Andrea joins the podcast to discuss a critical topic in clinical microbiology: antimicrobial susceptibility testing and breakpoints. Are labs using outdated breakpoints—and what does that mean for patient care? How are breakpoints determined and updated? Dr. Prinzi breaks it all down and shares insights from her article on the subject. Tune in to learn why staying current on breakpoints matters and what steps labs can take to improve antimicrobial stewardship. This episode was originally published on May 5th, 2022.   Check out the website: https://www.letstalkmicro.com/ Link to articles: https://asm.org/Articles/2022/February/Updating-Breakpoints-in-Antimicrobial-Susceptibili https://doi.org/10.1128/jcm.00106-25   Questions? Feedback? Send those to letstalkmicro@outlook.com Want to support the podcast? Here's how: Venmo: https://venmo.com/u/letstalkmicro Buy me a Ko-fi: https://ko-fi.com/letstalkmicro  

This week on Health Matters, we explore how to protect yourself from diseases carried by ticks and mosquitos. Dr. Jennifer Small-Saunders, an infectious disease expert with NewYork-Presbyterian and Columbia, explains why mosquitos are more attracted to some people than others. She also shares symptoms of diseases like West Nile Virus and Lyme Disease, how we can go about our summer activities without getting bitten, and what to do if you've been bitten.___Dr. Jennifer Small-Saunders is an Infectious Diseases physician-scientist who studies molecular mechanisms of antimalarial drug resistance in Plasmodium falciparum parasites. She is a practicing Infectious Diseases physician who sees patients on both the Internal Medicine and Infectious Diseases teaching services. She completed Internal Medicine residency and Infectious Diseases fellowship at Columbia University Irving Medical Center (CUIMC). Her postdoctoral studies investigated the landscape of mutations in the P. falciparum chloroquine resistance transporter PfCRT and how these mutations contribute to parasite resistance to chloroquine and piperaquine in Asia and Africa. Her group now uses mass spectrometry and gene editing techniques to study the role of tRNA modification reprogramming and translational control in resistance to the first line antimalarial, artemisinin.  The goal of her group is to uncover stress-response pathways in malaria parasites that can be targeted by new treatments.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine. To learn more visit: https://healthmatters.nyp.org

Jason Schwartz is an associate professor in the Department of Health Policy and Management at the Yale School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.L. Schwartz. Revised Recommendations for Covid-19 Vaccines — U.S. Vaccination Policy under Threat. N Engl J Med 2025;393:417-419.

From measles scares to shifts around COVID guidelines, vaccine conversations have gotten more complicated. Parents have questions about what's required for school, who qualifies for exemptions, and how to navigate conflicting advice from the CDC, social media, and their own doctors. The Commissioner of the Monroe County Department of Public Health joins us to cut through the noise and talk about vaccines and public health, and how her department is building trust in a time of science skepticism. In studio: Dr. Marielena Vélez de Brown, Commissioner of the Monroe County Department of Public Health Dr. Andrew Cox, associate director of Center for Infectious Disease and Immunology Research for RRH

Hear Christopher McKim's journey with moderate to severe plaque psoriasis and the latest clinical trial results from dermatologist, Dr. Christine Cornejo. Join this discussion with moderator Archie Franklin as Christopher McKim, a BMS employee living with moderate to severe plaque psoriasis, and Dr. Christine Cornejo, Director and US Medical Engagement Lead for Dermatology and Rheumatology at BMS, offer a patient and physician's perspective on treating plaque psoriasis from the inside. Listen as Chris presents his journey along with Dr. Cornejo addressing effectiveness and safety information with clinical trial results for a prescription oral treatment option. The intent of this episode is to encourage those who have moderate to severe plaque psoriasis to work with their health care provider to find a treatment option that is right for them. This episode is sponsored by Bristol Myers Squibb. For more information view Full Prescribing Information and Medication Guide . ·       (0:00)   Intro to Psoriasis Uncovered and guest welcome to Bristol Myers Squibb employee and patient Christopher McKim and Dr. Christine Cornejo, Director and US Medical Engagement Lead for Dermatology and Rheumatology at Bristol Myers Squibb. ·       (2:15)  Where the journey to finding the right treatment option for Chris and his moderate to severe plaque psoriasis began.  ·       (3:09)   The decision by Chris and his provider to try an oral systemic medication. ·       (3:28)  The effects and impact of an oral systemic treatment for Chris and his plaque psoriasis. ·       (4:09)   Dr. Cornejo addresses efficacy and clinical trials results. ·       (5:58)   Common side effects and safety concerns for the treatment Chris and his health care provider decided to try.   ·       (6:28)   Health considerations patients and providers should discuss prior to using a systemic treatment.    ·       (6:54)   What to do should side effects occur. ·       (7:10)   How Chris feels with clearer skin after making a change in treatment. ·       (8:14)   Indication and Important Safety Information. Key Takeaways: ·       Moderate to severe plaque psoriasis is a systemic disease.    ·       If you're ready to treat from the inside there is a treatment option that may help.   ·       Work with a health care provider to find the right treatment for moderate to severe plaque psoriasis.   ·       Be proactive by taking steps to learn about treatment options including effectiveness, side effects, safety concerns, and what should be discussed with a health care provider before beginning a new treatment for plaque psoriasis.  Guest Bios:   Christopher (Chris) McKim joined BMS in June of 2022. In his current role he is a Regional Marketer for the dermatology division, prior to that he provided support for 9 Therapeutic Area Specialists for the Pacific South District in the GI division.  Prior to joining BMS, Chris worked at Sanofi, J&J, Leo Pharma, and Sun Pharma in various field and home office roles. Chris resides in beautiful San Diego with his family Susan (wife), Morgan 18, Maddy 16, Mason 14 and two Golden Retrievers and enjoys traveling, cooking and anything associated with the ocean (Deep Sea Fishing, S.C.U.B.A. diving, snorkeling, and boogie boarding). Dr. Christine Cornejo joined Bristol Myers Squibb in 2024 as Director, Medical Engagement Lead for Dermatology and Rheumatology. Prior to joining BMS, she practiced dermatology at Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston, MA, where she specialized in melanoma and high-risk skin cancer management and served as the Director of Confocal Microscopy. She also served as an Instructor at Harvard Medical School and led the Immunology and Infectious Diseases course for 1st year medical students. Resources: Current Oral Systemic Treatments For additional questions about treatment options contact the NPF Patient Navigation Center

This member-driven podcast is a benefit of membership of the Arizona Chapter of the American Academy of Pediatrics (AzAAP) and is intended for AzAAP pediatric healthcare members.AzAAP would like to acknowledge the generous support of the podcast by the Arizona Department of Health Services through the Title V Maternal and Child Health Services Block Grant funding. No information or content in this podcast is intended to substitute or replace a consultation with a healthcare provider or specialist. All non-healthcare providers should reach out to their child's pediatrician for guidance. Music: Wallpaper by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/4604-wallpaperLicense: http://creativecommons.org/licenses/by/4.0/ 

On episode #85 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 7/3 – 7/21/25. Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Elimination of HIV Reservoirs Harboring Intact Proviruses (JID) Bacterial Expansion of tetM-Carrying Neisseria gonorrhoeae in the United States, 2018–2024 (NEJM) Study hints doxyPEP use coincides with rise in tetracycline-resistant gonorrhea in US (CIDRAP) Potential Impact of Doxycycline Post-Exposure Prophylaxis on Tetracycline Resistance in Neisseria gonorrhoeae and Colonization With Tetracycline-Resistant Staphylococcus aureus and Group A Streptococcus (CID) Methenamine hippurate asprophylaxis for recurrent urinary tract infections in older women – a triple-blind, randomised, placebo-controlled, phase IV trial (ImpresU). (CMI: Clinical Microbiology and Infection) Diagnosis and Management ofCommunity-acquired Pneumonia(American Journal of Respiratory and Critical Care Medicine) Complicated Urinary Tract Infections (cUTI): Clinical Guidelines for Treatment and Management (IDSA) The impact of an intervention to increase follow-up blood cultures for patients with Staphylococcus aureus bacteriuria (Antimicrobial Stewardship & Healthcare Epidemiology) Fungal The Last of US Season 2 (YouTube) Candida auris Containment Responses in Health Care Facilities that Provide Hemodialysis Services (CDC: MMWR) Candidozyma auris: an emerging threat (Reflections on Infectious Prevention and Control) Effects of postoperative antifungal therapy on the recurrence of Aspergillus infection after pulmonary aspergilloma resection (BMC Infectious Diseases) Triazole-resistant Aspergillus fumigatus in the Netherlands between 1994 and 2022: a genomic and phenotypic study (LANCET: Microbe) Large language models and their performance for the diagnosis of histoplasmosis (PLoS Neglected Tropical Diseases) Parasitic Field evidence of Trypanosoma cruzi infection, diverse host use and invasion of human dwellings by the Chagas disease vector in Florida, USA (PLoS Neglected Tropical Diseases) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

In this episode, we review the high-yield topic ⁠Pseudomonas Aeruginosa Infection ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Infectious Diseases section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

In this episode, we review the high-yield topic ⁠Dengue Fever⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Infectious Diseases section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

In this episode, we review the high-yield topic ⁠Malaria ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Infectious Diseases section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

In this episode, we review the high-yield topic ⁠Legionnaires Disease⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Infectious Diseases section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Health Secretary Robert F. Kennedy's revamped CDC vaccine advisory board stopped recommending certain flu vaccines this week. On this week's On the Media, a scientist debunks the claims that RFK, Jr.'s appointees are making. Plus, how the media covered the U.S. bombing of Iran.[00:00] Host Micah Loewinger unspools the Trump administration's attempts to control the narrative around the war in Iran, including the president's insistence on the “total obliteration” of Iran's nuclear sites, conflicting reports over whether or not Iran had a nuclear weapons program in the works, and how the media is missing the mark.[00:00] Host Brooke Gladstone speaks with Paul Offit, the director of the Vaccine Education Center and a physician in the Division of Infectious Diseases at Children's Hospital of Philadelphia, about how the Secretary of Health and Human Services, Robert F. Kennedy Jr., purged the CDC's vaccine advisory committee members, the controversial figures Kennedy replaced them with, and what impact this will have on the future of vaccines and immunology in the US. [00:00] Brooke continues her conversation with Paul Offit about the new controversial figures appointed to the CDC's vaccine advisory committee, and how science communication could improve in the next public health crisis.  Further reading:“Lawmakers and Pundits Speed Run Iraq WMDs-Level Lies About Iran,” by Sarah Lazare and Adam Johnson“Donald Trump and Sean Hannity Set Off a Wave of Disinformation After Iran Bombing,” by David Gilbert On the Media is supported by listeners like you. Support OTM by donating today (https://pledge.wnyc.org/support/otm). Follow our show on Instagram, Twitter and Facebook @onthemedia, and share your thoughts with us by emailing onthemedia@wnyc.org.